3G6.F GNI Group Ltd
- Market cap
- EUR 770M
- P/E
- -
- P/B
- 3.46x
- ROE
- -9.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 3G6.F undervalued?
Graham numberThe Graham number of GNI Group Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GNI Group Ltd fundamental analysis
No fundamental analysis for GNI Group Ltd yet.
GNI Group Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GNI Group Ltd
GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of pharmaceuticals and biomaterials in Japan, China, and the United States. It operates in two segments, Pharmaceutical Business and Medical Equipment Business. The company offers ETUARY for the treatment of idiopathic pulmonary fibrosis; H-GENIN Crush-Mix for the treatment of bone defects; AltiPly for the treatment of acute and chronic wounds; and orthobiologics pro…
Full company profileGNI Group Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GNI Group Ltd annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.31B | 2.65B | 5.02B | 7.45B | 9.77B | 12.7B | 17.4B | 26.0B | 23.6B | 26.8B | 23.9B |
| Gross Profit | 1.12B | 2.15B | 4.17B | 6.40B | 8.23B | 11.1B | 14.7B | 22.4B | 18.0B | 20.0B | 17.3B |
| Operating Income | -276M | 154M | 569M | 1.30B | 1.87B | 1.62B | 1.38B | 13.1B | 1.40B | -3.47B | 1.07B |
| EBITDA | - | 261M | 744M | 1.58B | 2.25B | 2.14B | 2.16B | 14.5B | 3.10B | -1.75B | 2.81B |
| Net Income | -513M | -175M | -200M | 182M | 1.26B | 1.07B | 389M | 8.09B | 1.10B | -4.24B | -3.98B |
| EPS | - | -4.33 | -4.81 | 4.19 | 29 | 22 | 8.19 | 162 | 22 | -76 | -71 |
| Balance Sheet | |||||||||||
| Total Assets | 5.82B | 15.9B | 17.3B | 20.6B | 23.2B | 30.3B | 33.9B | 62.4B | 71.9B | 83.8B | 81.8B |
| Total Liabilities | 1.29B | 2.40B | 3.61B | 7.51B | 10.5B | 11.0B | 14.1B | 26.3B | 32.2B | 32.1B | 15.3B |
| Shareholders' Equity | 3.26B | 11.7B | 12.0B | 10.7B | 11.0B | 18.9B | 21.0B | 33.8B | 36.4B | 50.2B | 40.4B |
| Cash & Short-term Investments | 2.60B | 4.19B | 4.87B | 7.67B | 10.3B | 14.4B | 11.0B | 21.6B | 10.1B | 21.1B | 17.2B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -518M | -476M | 621M | 788M | 1.38B | 552M | 393M | 5.00B | -3.16B | -2.41B | -3.21B |
| Capital Expenditure | 8.63M | 316M | 774M | 539M | 304M | 379M | 973M | 2.51B | 1.54B | 1.56B | 5.03B |
| Free Cash Flow | - | -636M | -235M | 176M | 1.02B | -142M | -1.55B | 2.49B | -4.70B | -3.97B | -8.24B |
| Ratios | |||||||||||
| ROE | -15.7% | -1.5% | -1.7% | 1.7% | 11.4% | 5.7% | 1.9% | 24.0% | 3.0% | -8.5% | -9.8% |
| ROA | -8.8% | -1.1% | -1.2% | 0.9% | 5.4% | 3.5% | 1.1% | 13.0% | 1.5% | -5.1% | -4.9% |
| Net Profit Margin | -39.3% | -6.6% | -4.0% | 2.4% | 12.9% | 8.4% | 2.2% | 31.1% | 4.7% | -15.8% | -16.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
GNI Group Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | JPY 150M | 3.16 | 14.1% |
| 2020 | JPY 150M | 3.45 | 11.9% |
| 2019 | EUR 150M | 3.46 | 82.5% |
| 2018 | EUR 150M | 3.61 | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:1 on Sep 2, 2019.
Who owns GNI Group Ltd
- Insiders 10.99%
- Institutions 10.36%
- Public & others 78.65%
- Shares outstanding 65.8M
- Free float 63.4M
GNI Group Ltd company profile
- Company name
- GNI Group Ltd
- Ticker
- 3G6.F
- ISIN
- JP3386370005
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 990
- Fiscal year end
- December
- Address
- Nihonbashi-Honcho YS Building, Chuo, Japan, 103-0023
- Phone
- 81 3 6214 3600
- Website
- gnipharma.com
About GNI Group Ltd
GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of pharmaceuticals and biomaterials in Japan, China, and the United States. It operates in two segments, Pharmaceutical Business and Medical Equipment Business. The company offers ETUARY for the treatment of idiopathic pulmonary fibrosis; H-GENIN Crush-Mix for the treatment of bone defects; AltiPly for the treatment of acute and chronic wounds; and orthobiologics products. It also develops ETUARY which is in Phase III clinical trial for the treatment of pneumoconiosis, dermatomyositis interstitial lung disease, and systemic sclerosis-associated interstitial lung disease; and F351 which is in Phase III clinical trial for the treatment of chronic hepatitis B liver fibrosis. In addition, the company is involved in the development of ETUARY which is in Phase II clinical trial for the treatment of radiation-induced lung injury with or without immune-related pneumonitis; F573 which is in Phase II clinical trial for the treatment of acute liver failure and acute-on-chronic liver failure; F351 which is in Phase I clinical trial for the treatment of MASH-advanced liver fibrosis; and F230 which is in Phase I clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops CG001419 which is in Phase Ia clinical trial for the treatment of acute and chronic pain; CG001419 which is in Phase Ia clinical trial for the treatment of solid tumors; and CG009301 which is in Phase Ia clinical trial for the treatment of leukemia and MYC+ cancers. The company was incorporated in 2001 and is headquartered in Chuo, Japan.
GNI Group Ltd management
10- Dr. Ying Luo Ph.D.CEO, President, Representative Executive Officer & Chair · born 1965
- Mr. Zhang PingExecutive Officer & Director · born 1973
- Dr. Kosuke TashiroCo-Founder
- Dr. Cristin PrintCo-Founder
- Dr. Stephen Charnock-JonesCo-Founder
- Mr. Ryosuke MatsuiExecutive Officer, VP, COO, CFO & Director · born 1979
- Cong Rong MuExecutive Officer and Head of President's Office, Accounting & Finance Division · born 1984
- Mr. Takuya Kaneko L.L.M.Executive Officer, CSO, GM of Administration Div, Head of Grp Alliance Prom Office
- Prof. Kan-ichiro Suzuki Ph.D.VP & Executive Officer · born 1954
- Kazuhiro KawauchiExecutive Officer & Chief Business Development Officer · born 1962